0ACX Stock Overview
A clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Centessa Pharmaceuticals plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$11.87 |
52 Week High | US$13.32 |
52 Week Low | US$8.49 |
Beta | 1.41 |
11 Month Change | 26.01% |
3 Month Change | n/a |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 27.22% |
Recent News & Updates
Recent updates
Shareholder Returns
0ACX | GB Biotechs | GB Market | |
---|---|---|---|
7D | -10.9% | 1.3% | 0.2% |
1Y | n/a | -18.7% | 11.2% |
Return vs Industry: Insufficient data to determine how 0ACX performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0ACX performed against the UK Market.
Price Volatility
0ACX volatility | |
---|---|
0ACX Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 6.0% |
Market Average Movement | 4.7% |
10% most volatile stocks in GB Market | 9.6% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0ACX's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0ACX's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2020 | 77 | Saurabh Saha | www.centessa.com |
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy.
Centessa Pharmaceuticals plc Fundamentals Summary
0ACX fundamental statistics | |
---|---|
Market cap | US$1.38b |
Earnings (TTM) | -US$157.35m |
Revenue (TTM) | US$6.85m |
201.9x
P/S Ratio-8.8x
P/E RatioIs 0ACX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0ACX income statement (TTM) | |
---|---|
Revenue | US$6.85m |
Cost of Revenue | US$0 |
Gross Profit | US$6.85m |
Other Expenses | US$164.20m |
Earnings | -US$157.35m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.39 |
Gross Margin | 100.00% |
Net Profit Margin | -2,296.03% |
Debt/Equity Ratio | 26.7% |
How did 0ACX perform over the long term?
See historical performance and comparison